ReviewNutrients2022
Role of Probiotics in the Management of COVID-19: A Computational Perspective.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05474144 (A Two-arm, Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy of the Probiotic Dietary Supplement SmartProbio C in the Supportive Supplementation of Patients With a Complicated Course of COVID-19 Infection), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two-arm, Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy of the Probiotic Dietary Supplement SmartProbio C in the Supportive Supplementation of Patients With a Complicated Course of COVID-19 Infection
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.Nutrition and health · 2026Pooled it
- Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases.BMC microbiology · 2022Pooled it
- Uncovering the Probiotic Supplement Landscape: Market Offerings, Sales Patterns, and Future Forecasts Using Machine Learning Approach - A Case Study of Montenegro.Probiotics and antimicrobial proteins · 2025Article
- Exploring the Therapeutic Landscape of Probiotics in Enteric and Respiratory Viral Infections.Probiotics and antimicrobial proteins · 2025Review
- Optimizing the Antimicrobial Effects by using Natural Compounds in COVID-19 Management.Current medicinal chemistry · 2025Review
- Heat-killedFrontiers in cellular and infection microbiology · 2025Article
- Alterations in Circadian Rhythms, Sleep, and Physical Activity in COVID-19: Mechanisms, Interventions, and Lessons for the Future.Molecular neurobiology · 2024Review
- Article
- Deciphering Microbial Shifts in the Gut and Lung Microbiomes of COVID-19 Patients.Microorganisms · 2024Article
- Resveratrol and Gut Microbiota Synergy: Preventive and Therapeutic Effects.International journal of molecular sciences · 2023Review
- Effect of probiotics as an immune modulator for the management of COVID-19.Archives of microbiology · 2023Article
- Intestinal Damage, Inflammation and Microbiota Alteration during COVID-19 Infection.Biomedicines · 2023Review
- Can Probiotics, ParticularlyBiology · 2023Review
- Observational
- Clinical Characteristics in the Acute Phase of COVID-19 That Predict Long COVID: Tachycardia, Myalgias, Severity, and Use of Antibiotics as Main Risk Factors, While Education and Blood Group B Are Protective.Healthcare (Basel, Switzerland) · 2023Article
- Article
- Host genetics and gut microbiota composition: Baseline gut microbiota composition as a possible prognostic factor for the severity of COVID-19 in patients with familial Mediterranean fever disease.Frontiers in microbiology · 2023Article
- Probiotics and Postbiotics as the Functional Food Components Affecting the Immune Response.Microorganisms · 2022Review
- The central role of the gut in intensive care.Critical care (London, England) · 2022Review
- Gut-Lung Microbiota Interaction in COPD Patients: A Literature Review.Medicina (Kaunas, Lithuania) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) was declared a pandemic at the beginning of 2020, causing millions of deaths worldwide. Millions of vaccine doses have been administered worldwide; however, outbreaks continue. Probiotics are known to restore a stable gut microbiota by regulating innate and adaptive immunity within the gut, demonstrating the possibility that they may be used to combat COVID-19 because of several pieces of evidence suggesting that COVID-19 has an adverse impact on gut microbiota dysbiosis. Thus, probiotics and their metabolites with known antiviral properties may be used as an adjunctive treatment to combat COVID-19. Several clinical trials have revealed the efficacy of probiotics and their metabolites in treating patients with SARS-CoV-2. However, its molecular mechanism has not been unraveled. The availability of abundant data resources and computational methods has significantly changed research finding molecular insights between probiotics and COVID-19. This review highlights computational approaches involving microbiome-based approaches and ensemble-driven docking approaches, as well as a case study proving the effects of probiotic metabolites on SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.